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98 Poster Session I110 (median age, 42, range; 18–75) were not. The two groups were
comparable with respect to age, gender, diagnosis, conditioning
regimens, number of TNCs infused, number of bags infused, total
volume infused, amount of DMSO and infusion rate. Patients re-
ceiving popsickle with strawberry aroma had significantly less nau-
sea (21.8% vs 6.6%, p 5 0.03) and had a trend for less vomiting
(13.6% vs 4.4%, p 5 0.1). Other infusion-related adverse events
were as follows; abdominal cramping, tachycardia, hypertension,
hypotension, chills, fever, sore throat and dyspnea. Incidences of
each of these adverse events were less than 3% in both groups and
were comparable. Conclusions: The use of popsickle with straw-
berry aroma during infusion of cryopreserved autologous PBSCs
significantly decreases infusion-related nausea, decreases vomiting
and recommended in this setting.
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DAPTOMYCIN PLUS CEFEPIME FOR MODERATE AND HIGH-RISK FE-
BRILE NEUTROPENIC PATIENTS WITH INCREASED RISK OF GRAM-POS-
ITIVE INFECTION
Rossetti, J.M., Thatikonda, C., Shadduck, R.K., Sahovic, E.,
Kaplan, R.B., Kennedy, M., Lister, J. Western Pennsylvania Cancer In-
stitute, Pittsburgh, PA.
Introduction: Febrile neutropenia following high dose chemo-
therapy or transplantation generally requires in-patient antimicro-
bial therapy. This vulnerable group of patients often has
indwelling catheters, which increase the risk of certain pathogens.
A focus of infection may not be clear, supporting the use of
a broad-spectrum regimen. As gram-positive bacteria are a leading
cause of infections in febrile neutropenic patients, vancomycin is
commonly used in the initial treatment regimen. The rising inci-
dence of vancomycin-resistance in many transplant units has
prompted the investigation of alternative agents. Methods: A pro-
spective pilot study was conducted utilizing daptomycin (6 mg/kg
IV q 24 hours) and cefepime for moderate to high-risk febrile neu-
tropenic patients with increased risk of gram-positive infections.
Eleven patients (10 male, 1 female) were enrolled, ages 40–82 yrs
(mean 5 58). Four patients were post-hematopoietic stem cell
transplant and 7 patients were post-intensive chemotherapy. The
regimen which resulted in defervescence (temperature\ 38C for
48 hours) was continued until ANC . 500 for 4 consecutive days.
Eight patients (73%) successfully completed empiric therapy, with
6 of them (55%) requiring no regimen alteration and 2 of them
(18%) requiring the addition of a broad empiric antifungal. Of
the 3 remaining patients (27%), 2 developed pneumonia and 1
grew an organism resistant to cefepime. Daptomycin was discontin-
ued in each of these 3 patients with appropriate changes made in
coverage. Results: All patients achieved defervescence with
a mean time to defervescence of 3 days (range 5 1–11 days). The
mean duration to resolution of all signs and symptoms of infection
was 3 days. Average length of hospital stay was 10 days (range5 4–
23). At least 4 patients were able to receive the drug on an out pa-
tient basis, reducing their total hospital stay by 1–3 days. There
were no readmissions due to drug failure in the 1-week follow up pe-
riod. There were no ICU admissions, deaths or treatment-limiting
toxicities. The most common non-hematological toxicities were hy-
poalbuminemia, high alkaline phosphatase and mild electrolyte ab-
normalities. Conclusion: Daptomycin could be a safe and effective
alternative to vancomycin in the initial regimen for febrile neutro-
penia. Bactericidal activity and activity against many resistant or-
ganisms may reduce duration of fever and associated outcomes.
Once daily dosing may allow outpatient administration.
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USEFULNESS OF BRONCHOSCOPIC LAVAGE IN INTENSIVE CARE UNIT
FOR CRITICALLY ILL STEM CELL TRANSPLANT RECIPIENTS WITH PUL-
MONARY INFILTRATES
Ghosh, S., Finch, C.G., Champlin, R.E., Kebriaei, P., Giralt, S.A.,
Pravinkumar, S.E. The University of Texas MD Anderson Cancer Cen-
ter, Houston, TX.
Background: Acute hypoxemic respiratory failure (AReF) with
pulmonary infiltrates is the most frequent cause for critical care ad-
missions amongst stem cell transplant (SCT) recipients. Pulmonary
infiltrates in cancer patients are nonspecific and can be caused by in-fection, acute lung injury and also by tumor, radiation and chemo-
therapy. Diagnosis of pulmonary infection by chest x-ray has
a sensitivity of 92% but a specificity of only 33%, rendering mico-
biological diagnosis a challenge. We studied the diagnostic yield
and usefulness of bronchoscopic bronchoalveolar lavage (B-BAL)
in critically-ill SCT recipients. Methods: Following IRB approval,
medical records of critically-ill cancer patients admitted to the on-
cological intensive care unit (ICU), with a clinical suspicion of
pneumonia that underwent B-BAL between 5/1/2006 and 10/30/
2006 were reviewed retrospectively. Recipients of SCT with pulmo-
nary infiltrates and AReF were included in this study. B-BAL sam-
ples were obtained from the radiographic sites of infiltrates and sent
for microbiological analysis. Results: During the six-month study
period, 105 critically-ill adult patients underwent B-BAL of which
20 (19%) were SCT recipients. Sixty percent SCT recipients had
lymphoid and 40% myeloid malignancies. Fifteen patients had re-
ceived allogeneic transplants (unrelated 7, haploidentical 5, siblings
2, cord blood 1) and 5 had autologous transplants. The patients
were a median of 119 days post-SCT (range: 6–1189). Only one pa-
tient had received SCT within the prior 3 weeks. Ninety percent of
SCT recipients had radiographic evidence of pulmonary infiltrates
and were mechanically ventilated. Significant microorganisms were
isolated in 63% cases with identification of bacteria 42%, virus 26%
and fungi 21%. The microbiology and related outcomes are shown
in Table 1. Concurrent infections in extra pulmonary sites were
present in 37% of SCT recipients. Respiratory failure was present
in all patients who died.Conclusion: Positive microbiological yield
was obtained by B-BAL in more than half of SCT recipients admit-
ted to ICU with pulmonary infiltrates. AReF with pulmonary infil-
trates is a serious condition in SCT recipients and B-BAL should be
considered as a useful test, early in the management of critically-ill
SCT recipients with pulmonary infiltrates.
B-BAL Microbiological yield & Outcomes in Critically-ill SCT
Recipients
Microorganisms nBacteria
Coagulase Negative Staphylococcus 3
Xanthomonas Maltophilia 2
Enterococcus spp. 2
Klebsiella pneumoniae 1
Legionella spp. 1
Acenitobacter calcoaceticus-baumannii complex 1
Vancomycin Resistant Enterococcus 1Virus
Parainfluenza 2
Adenovirus 2
Cytomegalovirus Antigen 1Fungus
Candida glabarata 2
Mold (Microsporum and Paecilomyces spp.) 2ICU Outcome
Length of stay in days, median (range) 14 (1–32)
Alive 9 (45%)
Dead 11 (55%)Hospital Outcome
Length of stay in days, median (range) 39 (1–84)
Alive 5 (25%)
Dead 15 (75%)267
LARGER STEM CELL DOSE IS ASSOCIATED WITH DECREASED SYMPTOM
SEVERITY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR
MULTIPLE MYELOMA
Williams, L.A.1, Giralt, S.A.2, Mendoza, T.R.1, Anderson, K.O.1,
Mobley, G.M.1, Saliba, R.M.2, Qazilbash, M.H.2, Campagnaro, E.L.3,
Cleeland, C.S.1 1The University of Texas MD Anderson Cancer Center,
Houston, TX; 2The University of Texas MD Anderson Cancer
Center, Houston, TX; 3University of Michigan Comprehensive Cancer
Center, Ann Arbor, MI.
Poster Session I 99Significance: High-dose chemotherapy with autologous stem
cell transplantation (HDC-AuSCT) has become an established pro-
cedure for treatment of multiple myeloma (MM). During HDC-
AuSCT, patients develop a symptom burden that substantially
interferes with daily activities. Theoretical Framework: Symptom
burden is the combined impact of all symptoms on one’s ability to
function as one did before onset of disease and therapy. Problem
and Purpose: Minimizing the symptom burden of HDC-AuSCT
may allow more patients the chance to receive its demonstrated ben-
efits. The purpose of this research was to explore the ability of larger
numbers of CD341 cells to decrease symptom severity during
HDC-AuSCT in patients with MM. Methods: This was a retro-
spective analysis of 17 patients with MM who completed the M.
D. Anderson Symptom Inventory (MDASI) (0–10 measurement
scale) at 6 time points from baseline to 30 days post-HDC-AuSCT.
Four patients received high doses of stem cells (9.5–15  106
CD341 cells/kg) and 13 received standard doses (4–6  106
CD341 cells/kg). Area under the curve (AUC) methodology was
used to describe the severity of the 5 most severe symptoms (fatigue,
lack of appetite, difficulty sleeping, nausea, and pain) that these pa-
tients experienced during the peritransplantation period. Results:
Means and standard deviations of symptom severity measures are
in Table 1. The mean symptom severity of the 2 groups showed
no difference at baseline. The difference in mean daily AUC be-
tween the 2 groups from cell infusion to 30 days post-HDC-AuSCT
approached significance and, more importantly, showed a large ef-
fect size of 1.2 times the common group standard deviation. The
mean symptom severity of the 5 most severe symptoms was signif-
icantly lower at nadir for the group receiving the high cell dose. Im-
plications: The mean symptom severity for the 2 groups began to
diverge sharply after cell infusion. The severity for patients receiv-
ing the larger cell dose declined immediately, whereas the severity
for patients receiving the standard cell dose rose further before de-
clining. The use of larger cell doses to decrease symptoms warrants
prospective testing in a randomized controlled trial. The mecha-
nism behind the ability of larger doses of stem cells to ameliorate
symptom severity is unclear. The known relationship between
symptom development and severity and inflammatory cytokines
(e.g., IL-6) suggests a possible cytokine-based mechanism, which
also should be explored.
Table 1. Symptom Severity during Autologous Stem Cell
Transplantation for Multiple Myeloma
Larger Cell Standard
Dose Cell DoseMeasure Mean SD Mean SD
P Value
(2-Tailed)Severity at baseline
of 5 most severe
symptoms1.35 1.06 1.86 1.71 0.49Severity at nadir
of 5 most severe
symptoms2.55 1.68 6.06 2.26 \0.012Daily AUC of 5 most
severe symptoms63.55 42.02 122.95 51.24 0.053SD 5 standard deviation.268
UPDATE ON FUNGAL INFECTIONS IN PEDIATRIC BONE MARROW
TRANSPLANT PATIENTS AT THE MATTEL CHILDREN’S HOSPITAL AT
UCLA FROM 1991–2006
Simms-Waldrip, T.R., Rosen, G.P., Kempert, P.H., Nielsen, K.,
Moore, T.B. DavidGeffen School ofMedicine at UCLA, Los Angeles, CA.
Objectives:To identify changes in fungal organisms and charac-
teristics of their infections over time in pediatric bone marrow
transplant (BMT) patients. Identify differences in fungal species
causing infections in different BMT patients. Methods: We per-
formed a retrospective cohort study of all 324 patients on the pedi-atric hematology and oncology service at UCLA between 1991 and
2006 who underwent bone marrow transplantation. Cultures posi-
tive for fungus were identified from both the microbiology lab da-
tabase as well as medical record review to identify eighty-three
unique infections in fifty-four transplant patients. Results: The
overall incidence of fungal infections in BMT recipients was
16.7%. The predominant organisms included: Candida species
(55%) and Apergillus species (21%), with Candida albicans account-
ing for 19% of all fungal species. A variety of other fungal species
comprised the remainder of infections. The distribution of organ-
isms over time demonstrated a strong trend towards an increase
in rare molds in more recent years. The respiratory tract was the
main site of infection (41%) with urine (17%) and blood (11%)
also noted as significant sites. Upon stratification of the BMT pa-
tients who developed fungal infections, the primary diagnoses
were ALL (48%) and myeloid malignancy (35%); underlying diag-
nosis, however, had little impact on the development of a fungal in-
fection in BMT patients. Of all deaths in the studied population,
fungal-related mortality of patients analyzed was 44%. Conclu-
sions: Bone marrow transplant patients have a high risk of fungal
infections, likely secondary to their severe and prolonged neutrope-
nia. This risk appears to be increasing over time with rarer organ-
isms becoming more prevalent. This emphasizes the need for the
development and implementation of improved diagnostic and ther-
apeutic strategies in order to improve survival in this population.269
A PHASE II OPEN LABEL PILOT TRIAL OF EMPIRIC DAPTOMYCIN TREAT-
MENT FOR HEMATOLOGY-ONCOLOGY PATIENTS WITH FEBRILE NEU-
TROPENIA (FN)
Bubalo, J.S.1, Ciszewski, A.O.1, Kovascovics, T.J.1, Meyers, G.1,
Mauro, M.1, Epner, E.1, Jones, N.1, Hayes-Lattin, B.1,
Deninger, M.1, Curtin, P.T.2, Leis, J.F.2, Maziarz, R.T.1 1Oregon
Health and Sciences University Hospital, Portland, OR; 2University of
California San Diego, San Diego, CA; 3Mayo Clinic, Phoenix, AZ.
FN warrants prompt attention and treatment due to potential for
associated morbidity and mortality. Broad spectrum antibiotics are
guided by putative causative organisms. Initially gram-negative and
then gram positive organisms have emerged as infectious culprits.
Therefore vancomycin is often added in FN patients still febrile af-
ter 72 hours of initial antibiotic therapy. Emerging antibiotic resis-
tance by gram-positive organisms and the bacteriostatic nature of
vancomycin, make the study of new gram-positive therapies like
the novel bactericidal, antibiotic daptomycin, critical. This pilot
study aims to determine initial efficacy, safety, and pharmacokinet-
ics (PK), of daptomycin substituted for vancomycin in FN patients.
FN patients, without pneumonia, were enrolled and received dapto-
mycin per the current IDSA FN guidelines. Patients received 6 mg/
kg as a 30 minute intravenous infusion every 24 hours. Blood sam-
ples for measurement of plasma daptomycin concentrations were
collected for PK analysis. Twenty-eight patients, 19 men/9 women,
age range 24–74 years old (median 53) have been treated. Their
weights ranged from 56.2–137 kg (median of 89.9 kg). The patient’s
had the following malignancies: 10 AML, 6 ALL, 2 multiple mye-
loma, 2 Hodgkin’s disease, 2 non-Hodgkin’s lymphoma, 1 APL,
and 1 germ cell tumor. Ten patients were post autologous and 5
post allogeneic transplants, with 13 receiving non-transplant che-
motherapy. The median and mean time to reach an afebrile state
was 4 days. Mean duration receiving daptomycin was 11 days (me-
dian 8, range 3–40 days). Infectious organisms, identified for 16/28
patients, included: coagulase-negative S. aureus, alpha-hemolytic
streptococcus, S. mitis, S. oralis, P. aeruginosa, K. pneumonia, Co-
rynebacterium, and E. coli. One patient developed a drug rash
which abated after the cessation of daptomycin, and 1 experienced
mental status changes considered possibly related to taking dapto-
mycin. One patient stopped daptomycin secondary to parotitis for
which no organism was identified but improved when the patient
was changed to vancomycin. No patients experienced myositis or el-
evations in CK levels while on daptomycin. Daptomycin was safe
with no breakthrough gram positive infections and a mean time to
defervescence of 4 days. This pilot study supports future evaluation
